Yuliya Spencer
Psychiatric/Mental Health · Birmingham, ALNPI 1407227861
Payments from drug & device makers
Across 776 payments — averaging $83.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$53K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$993
- plus $4K from 12 others
What the payments were for
- Speaking & faculty fees$50,05078%
- Travel & lodging$1,2762%
- Food & beverage$13,13320%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 179 | $53,257 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 116 | $2,258 |
| Neurocrine Biosciences, Inc. | 69 | $1,802 |
| Alkermes, Inc. | 66 | $1,309 |
| Teva Pharmaceuticals USA, Inc. | 88 | $1,080 |
| Johnson & Johnson | 51 | $993 |
| Otsuka America Pharmaceutical, Inc. | 53 | $941 |
| Vanda Pharmaceuticals Inc. | 42 | $873 |
| E.r. Squibb & Sons, L.L.C. | 28 | $535 |
| Lundbeck LLC | 22 | $458 |
| Indivior Inc. | 28 | $452 |
| Axsome Therapeutics, Inc. | 12 | $269 |
| Sunovion Pharmaceuticals Inc. | 12 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Corium, LLC | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $22 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$51,396
- ARISTADA$500
- CAPLYTA$250
- ARISTADA INITIO$125
How this compares
$64,567 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 328 | $1,041,602 |
| AustedoDeutetrabenazine | 88 | $557,345 |
| Invega HafyeraPaliperidone Palmitate | 27 | $538,093 |
| IngrezzaValbenazine Tosylate | 53 | $440,726 |
| Abilify MaintenaAripiprazole | 98 | $287,131 |
| AristadaAripiprazole Lauroxil | 76 | $259,150 |
| VraylarCariprazine Hcl | 164 | $253,547 |
| UzedyRisperidone | 38 | $138,361 |
| Invega TrinzaPaliperidone Palmitate | 18 | $130,619 |
| CaplytaLumateperone Tosylate | 40 | $84,447 |
| Abilify AsimtufiiAripiprazole | 13 | $76,629 |
| Risperidone ErRisperidone Microspheres | 27 | $56,867 |
| Aripiprazole | 308 | $39,238 |
| Risperdal ConstaRisperidone Microspheres | 13 | $33,804 |
| TrintellixVortioxetine Hydrobromide | 37 | $30,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $993 | $1,206,026359 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy, Loxapine | $1,080 | $699,191177 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,802 | $440,72653 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $941 | $363,761111 claims |
| Alkermes, Inc.Aristada | $1,309 | $259,15076 claims |
| AbbVieVraylar | $53,257 | $253,547164 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,258 | $84,44740 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $76 | $30,22437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Birmingham
- David CoffmanBirmingham$13K
- Tiffany WallerBirmingham$12K
- Kellie VaughnBirmingham$12K
- Amanda BoydBirmingham$10K
- Hannah KeslerBirmingham$9K
- Judy ClarkBirmingham$9K
- Jessica AdwellBirmingham$9K
- Pamela Kite TrullBirmingham$9K
- Lacey PodyBirmingham$7K
- Emily MartinBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.